share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K：重大事件
美股sec公告 ·  03/18 15:35
Moomoo AI 已提取核心訊息
Novo Integrated Sciences, Inc. reported on March 18, 2024, that it has entered into an Assignment of Security Purchase Agreement and Promissory Note with RC Consulting Group LLC and RC Consulting Consortium Group LLC. This assignment involves the transfer of all rights and interests in a previously agreed securities purchase agreement and an unsecured 15-year promissory note, originally issued on April 26, 2023, with a principal sum of $70,000,000. The note, which matures on April 26, 2038, includes a yield of 1.52% per annum and contains standard events of default provisions. The company also addressed a prior notification from Nasdaq on February 9, 2024, indicating non-compliance with minimum bid price requirements, which was considered an event of default under the terms of the securities purchase agreement and the note. However, a Limited Waiver was agreed upon with the Holder to exempt any non-compliance related to the minimum bid price requirement. The assignment does not affect the terms of the securities purchase agreement and the note, which remain in full force and effect, except as amended by the waiver.
Novo Integrated Sciences, Inc. reported on March 18, 2024, that it has entered into an Assignment of Security Purchase Agreement and Promissory Note with RC Consulting Group LLC and RC Consulting Consortium Group LLC. This assignment involves the transfer of all rights and interests in a previously agreed securities purchase agreement and an unsecured 15-year promissory note, originally issued on April 26, 2023, with a principal sum of $70,000,000. The note, which matures on April 26, 2038, includes a yield of 1.52% per annum and contains standard events of default provisions. The company also addressed a prior notification from Nasdaq on February 9, 2024, indicating non-compliance with minimum bid price requirements, which was considered an event of default under the terms of the securities purchase agreement and the note. However, a Limited Waiver was agreed upon with the Holder to exempt any non-compliance related to the minimum bid price requirement. The assignment does not affect the terms of the securities purchase agreement and the note, which remain in full force and effect, except as amended by the waiver.
Novo Integrated Sciences, Inc.於2024年3月18日報告稱，它已與RC諮詢集團有限責任公司和RC諮詢聯盟集團有限責任公司簽訂了證券購買協議和期票轉讓協議。該轉讓涉及先前商定的證券購買協議和一份最初於2023年4月26日發行的15年期無抵押本票中的所有權利和權益的轉讓，本金爲7000萬美元。該票據將於2038年4月26日到期，年收益率爲1.52％，幷包含違約條款的標準事件。該公司還於2024年2月9日回覆了納斯達克事先發出的通知，該通知表明沒有遵守最低出價要求，根據證券購買協議和票據的條款，這被視爲違約事件。但是，與持有人商定了有限豁免，以豁免與最低出價要求相關的任何違規行爲。該轉讓不影響證券購買協議和票據的條款，除非經豁免修訂，否則這些條款仍然完全有效。
Novo Integrated Sciences, Inc.於2024年3月18日報告稱，它已與RC諮詢集團有限責任公司和RC諮詢聯盟集團有限責任公司簽訂了證券購買協議和期票轉讓協議。該轉讓涉及先前商定的證券購買協議和一份最初於2023年4月26日發行的15年期無抵押本票中的所有權利和權益的轉讓，本金爲7000萬美元。該票據將於2038年4月26日到期，年收益率爲1.52％，幷包含違約條款的標準事件。該公司還於2024年2月9日回覆了納斯達克事先發出的通知，該通知表明沒有遵守最低出價要求，根據證券購買協議和票據的條款，這被視爲違約事件。但是，與持有人商定了有限豁免，以豁免與最低出價要求相關的任何違規行爲。該轉讓不影響證券購買協議和票據的條款，除非經豁免修訂，否則這些條款仍然完全有效。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息